-
J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth
•
Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for the fourth quarter and full year of 2023. Fourth-quarter global sales increased by 7.2% excluding currency impacts to USD 21.4 billion, while full-year revenues rose by 7.4% year-on-year (YOY) to USD 85.16 billion. Both the…
-
Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for the fiscal year ending December 31, 2023. The company expects to report revenues within the range of RMB 124-126 million (USD 17.2-17.5 million), a significant increase compared to the RMB 12.8 million (USD 1.78 million)…
-
Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast
•
Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen Inc. (NASDAQ: SGEN), with the deal set to close today. The US pharmaceutical giant had to make concessions to address the US Federal Trade Commission’s (FTC) concerns over…
-
WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall
•
WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December 4, 2023, following an investor presentation that disclosed the contract development manufacturing organization (CDMO) industry’s growth has slowed to single digits, down from over 15% in recent years. The company’s business update revealed that its…
-
Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services
•
Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results for the first half of 2023, ending September 30, reporting revenues of RMB 12.956 billion. This represents a year-on-year increase of 12.7%, driven by robust growth in its pharmaceutical self-operated business as well as its…
-
Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials
•
Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published its financial results for the third quarter of 2023. The company reported revenues of RMB 3.9278 billion (USD 542 million) for the nine months ending September 30, 2023, marking an impressive 84.0% year-on-year (YOY) increase.…
-
CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments
•
China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter of 2023. The company reported a 13.5% decrease in sales, amounting to USD 8.8 million. Despite this downturn, several positive developments indicate a promising outlook for the company in the near future. Revenue Generator and…
-
Lundbeck A/S Reports 7% YOY Revenue Increase in Q3 2023 and 9% Growth for the First Three Quarters
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-A) has announced its financial results for the third quarter and the first three quarters of 2023. The company reported a 7% year-on-year (YOY) increase in revenues in constant currency terms for the three-month period, reaching DKK 4.952 billion (USD 709 million). For…
-
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
•
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023, revealing a 4.1% year-on-year (YOY) decline in organic sales, totaling EUR 5.2 billion (USD 5.5 billion) for the three-month period. The results highlight a challenging environment, with only the Healthcare division showing growth. The Healthcare…
-
BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the third quarter of 2023. The biotechnology company reported total revenues of USD 781 million, with global product sales reaching USD 595 million, marking year-on-year (YOY) increases of 102% and 70%, respectively. Net profits for the…
-
AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third quarter of 2023, showing a total revenue increase of 6% year-on-year (YOY) to USD 11.5 billion in constant currency terms. Product sales accounted for USD 11.02 billion, marking a 5% YOY increase. Excluding COVID-19 medicines,…
-
Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth
•
Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023, revealing global sales of EUR 35.8 billion (USD 38.3 billion) between Q1 and Q3, marking a 3.2% year-on-year (YOY) decline. Despite this, the company confirmed its 2023 guidance of EUR 48.5 billion to EUR 49.5…
-
Viatris Inc. Reports Q3 2023 Global Net Sales Growth of 1% and Highlights from Earnings Call
•
US-based generics giant Viatris Inc., (NASDAQ: VTRS) has released its financial results for the third quarter of 2023. The company reported global net sales of USD 3.93 billion, marking a 1% year-on-year (YOY) increase in constant currency terms. Geographical Sales BreakdownViatris Inc.’s sales performance varied by region. Developed and Emerging…
-
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
•
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third quarter of 2023, showcasing a significant year-on-year (YOY) increase in global sales. The company’s revenues rose by 155% to USD 40.1 million, reflecting the success of its anti-anemia drug for chronic kidney disease (CKD), Evrenzo…
-
Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing a 33% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 166.4 billion (USD 23.7 billion) over the first nine months. The company identified diabetes care and obesity care as the key growth drivers,…
-
Innovent Biologics Reports Q3 2023 Sales Exceeding RMB 1.6 Billion with 45% YOY Growth
•
Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced its product sales for Q3 2023, which exceeded RMB 1.6 billion (USD 219 million), marking a 45% increase year-on-year (YOY). The company’s PD-1 inhibitor, Tyvyt (sintilimab injection), continued to show strong market performance, and there was…
-
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
•
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter of 2023, showing a 36% year-on-year (YOY) increase in sales to USD 9.5 billion in constant currency terms. This figure includes a USD 1.42 billion one-off payment from the sale of the Zyprexa (olanzapine) portfolio…
-
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
•
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023, showing a 1% year-on-year (YOY) decrease in sales to USD 1.519 billion in constant currency terms. The company’s performance was marked by a 7% decline in Women’s Health sales to USD 418 million, a 10%…
-
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
•
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third quarter of 2023, reporting a contraction of -41% year-on-year (YOY) in operational terms to USD 13.2 billion, excluding foreign currency fluctuations. The quarter was marked by a net loss of USD 2.38 billion, the company’s…
